- Home
- MDGL vs BYD Comparison
MDGL vs BYD Comparison
Compare MDGL & BYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | BYD |
|---|---|---|
| Founded | 2011 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 6.7B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MDGL | BYD |
|---|---|---|
| Price | $541.66 | $83.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | ★ $674.45 | $90.91 |
| AVG Volume (30 Days) | 335.0K | ★ 792.3K |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | 41.32 | ★ 264.46 |
| EPS | N/A | ★ 22.56 |
| Revenue | $180,133,000.00 | ★ $2,626,730,000.00 |
| Revenue This Year | $58.28 | $2.13 |
| Revenue Next Year | $46.80 | $2.66 |
| P/E Ratio | ★ N/A | $3.71 |
| Revenue Growth | N/A | ★ 9.41 |
| 52 Week Low | $265.00 | $58.94 |
| 52 Week High | $615.00 | $89.96 |
Technical Indicators
Market Signals| Indicator | MDGL | BYD |
|---|---|---|
| Relative Strength Index (RSI) | 74.28 | 53.15 |
| Support Level | $535.33 | $81.24 |
| Resistance Level | $572.20 | $86.16 |
| Average True Range (ATR) | 26.99 | 2.40 |
| MACD | 11.83 | 0.25 |
| Stochastic Oscillator | 82.48 | 65.37 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.